Patents Assigned to Bristol-Myers Squibb Pharma
  • Cyclic malonamides as inhibitors of A-? protein production
    Patent number: 7053081
    Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: May 30, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard E. Olson, Michael G. Yang
  • Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same
    Patent number: 7049412
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Pharma Comp.
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7045521
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: May 16, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Robert Cherney
  • Pyrazolotriazines as CRF antagonists
    Patent number: 7026317
    Abstract: The present invention relates to pyrazolotriazines according to formula (I) and stereoisomers, isomers and salts thereof wherein R1-R5 are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: April 11, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul J. Gilligan, Richard G. Wilde
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 7018611
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: October 26, 2002
    Date of Patent: March 28, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
  • Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
    Patent number: 7015214
    Abstract: The present invention relates to 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: March 21, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donna M Bilder
  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent number: 7005435
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P—M—M4I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5–7 membered carbocycle or heterocycle and ring M is a 5–7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: February 28, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald J. P. Pinto, Michael J. Orwat, Patrick Y. S. Lam
  • 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
    Patent number: 6998408
    Abstract: The present application describes 6–5, 6—6, or 6–7 heterobicycles of Formula I or pharmaceutically acceptable salt forms thereof: wherein ring P is a 6-membered heteroaromatic and ring M is a 5-, 6-, or 7-membered non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: February 14, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donald Joseph Philip Pinto
  • Composition comprising low density microspheres
    Patent number: 6998107
    Abstract: Low density microspheres, methods for preparing same, and use of same as contrast agents are described. The microspheres have a void having a volume that comprises at least about 75% of the total volume of the microspheres, and which contains a gas or the vapor of a volatile liquid selected from the group consisting of aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes and perfluorocarbons.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: February 14, 2006
    Assignee: Bristol-Myers Squibb Pharma Comapany
    Inventor: Evan C. Unger
  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent number: 6995172
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5–7 membered carbocycle or heterocycle and ring M is a 5–7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: February 7, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y. S. Lam, Stephanie L. Koch
  • Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
    Patent number: 6994852
    Abstract: Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: February 7, 2006
    Assignees: Temple University-of the Commonwealth System of Higher Education, Bristol-Myers Squibb Pharma Company
    Inventors: Robert W. Colman, Shaker A. Mousa
  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent number: 6989391
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: January 24, 2006
    Assignee: Bristol-Myers-Squibb Pharma Company
    Inventors: Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Jennifer X. Qiao, Patrick Y. S. Lam, Stephanie L. Koch
  • Matrix metalloproteinase inhibitors
    Patent number: 6989139
    Abstract: Thus the present invention describes novel compounds comprising 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits and their uses in treatment of diseases associated with MMPs.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: January 24, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Carl P. Decicco, David J. Nelson, John A. Barrett, Alan P. Carpenter Jr., Jingwu Duan, Milind Rajopadhye
  • Piperidine amides as modulators of chemokine receptor activity
    Patent number: 6984651
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma, Company
    Inventors: John V. Duncia, Joseph B. Santella, Dean A. Wacker, Wenqing Yao, Changsheng Zheng
  • Cyclic ?-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-?
    Patent number: 6984648
    Abstract: The present application describes novel cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-? inhibitors.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Jr., Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Matrix metalloproteinase inhibitors
    Publication number: 20050287074
    Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
    Type: Application
    Filed: August 1, 2005
    Publication date: December 29, 2005
    Applicant: Bristol-Myers Squibb Pharma Company
    Inventors: Alan Carpenter, Milind Rajopadhye
  • Diamines as modulators of chemokine receptor activity
    Patent number: 6974836
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 13, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Percy Carter, Robert Cherney
  • Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
    Patent number: 6974567
    Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: December 13, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: David Scott Edwards, Shuang Liu
  • Piperizinones as modulators of chemokine receptor activity
    Patent number: 6974869
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: December 13, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: George V. DeLucca
  • Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6969721
    Abstract: The present invention relates to tricyclic 2-pyridone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: November 29, 2005
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: James D. Rodgers, Haisheng Wang, Mona Patel, Argyrios Arvanitis, Anthony J. Cocuzza